|
All Releases
 |
SIGA Receives $8 Million in Financing Support from MacAndrews & Forbes
Jun 23, 2008
|
11.3 KB |
|
| |
NEW YORK, Jun 23, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that one of its largest investors, MacAndrews & Forbes LLC, has agreed to supply as needed up to $8.0 million in financing.
Under the agreement, ...
|
|
SIGA Advances Dengue Antiviral Program
May 21, 2008
|
12.8 KB |
|
| |
NEW YORK, May 21, 2008 (PrimeNewswire via COMTEX News Network) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it has completed a screen of a proprietary small-molecule chemical library in support of its Dengue fever antiviral program. T...
|
|
SIGA Technologies Reports Operating Results for the First Quarter of 2008
May 12, 2008
|
12.0 KB |
|
| |
NEW YORK, May 12, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its results of operations for the first quarter of 2008.
Revenues for the quarter ended March 31, 2008 were $2.0 million, virtually even with last yea...
|
|
SIGA Adds Vice President of Clinical and Regulatory Affairs to Management Team
May 7, 2008
|
10.9 KB |
|
| |
NEW YORK, May 07, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced the appointment of Seane Jones as the new Vice President of Clinical and Regulatory Affairs, effective April 29, 2008. Ms. Jones will direct the executio...
|
|
SIGA Technologies to Announce First Quarter 2008 Results of Operations on May 12, 2008
May 6, 2008
|
11.4 KB |
|
| |
NEW YORK, May 06, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, plans to announce its first quarter 2008 results in a press release that will be issued on Monday, May 12, 2008 before the market open. The Company has scheduled a confer...
|
|
SIGA Begins Negotiations with Government Agency for Additional Funding to Accelerate ST-246 Commercial Scale Manufacturing
Apr 29, 2008
|
10.9 KB |
|
| |
NEW YORK, Apr 29, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it has begun negotiations with the National Institute of Allergy and Infectious Diseases (NIAID) to obtain supplemental funding for its existing $16....
|
|
Dr. Dennis E. Hruby, Chief Science Officer of SIGA Technologies, to Present CDC Distinguished Lecture on Smallpox Antiviral Drug ST-246
Apr 18, 2008
|
11.8 KB |
|
| |
NEW YORK, Apr 18, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, announced today that its Chief Scientific Officer, Dr. Dennis E. Hruby, is presenting a Distinguished Lecture at the Centers for Disease Control and Prevention (CDC) in Atlanta on Wedn...
|
|
SIGA Advances ST-246 Smallpox Antiviral Development in Europe
Apr 15, 2008
|
12.5 KB |
|
| |
NEW YORK, Apr 15, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that its subsidiary, SIGA Pharmaceuticals (Europe) Limited, has qualified as a 'small and medium-sized enterprise' (SME) with respect to its application f...
|
|
SIGA Initiates Manufacture of ST-246 NDA Registration Batches
Apr 4, 2008
|
10.2 KB |
|
| |
NEW YORK, Apr 04, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced the company has initiated the activities necessary to produce the NDA registration batches of its lead smallpox antivi...
|
|
SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial
Mar 27, 2008
|
12.3 KB |
|
| |
NEW YORK, Mar 27, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, announced today that it has successfully completed a multiple ascending dose human clinical trial with its lead smallpox drug candidate, ST-246. Volunteers received oral...
|
|
SIGA Files Application Supporting Emergency Use Approval for ST-246
Mar 24, 2008
|
12.2 KB |
|
| |
NEW YORK, Mar 24, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has submitted to the FDA an application to support an Emergency Use Authorization (EUA) of its drug ST-246, an orally active, smallpox antiviral, ...
|
|
SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel
Mar 17, 2008
|
9.1 KB |
|
| |
NEW YORK, Mar 17, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced it has retained KCSA Strategic Communications to implement a comprehensive investor relations program.
Commenting on the appointment, Eric A. Rose, MD...
|
|
SIGA to Present at Susquehanna's SIGnificant Options in Healthcare Conference
Feb 29, 2008
|
8.2 KB |
|
| |
NEW YORK, Feb 29, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Executive Officer, Dr. Eric Rose, will present an overview of the company's business activities at the ...
|
|
SIGA to Present at The 26th Annual JPMorgan Healthcare Conference
Jan 7, 2008
|
7.2 KB |
|
| |
New York, New York, January 7, 2008 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Executive Officer, Dr. Eric Rose, will present an overview of the company̵...
|
|
SIGA CEO, Dr. Eric Rose, Selected To Serve As Member of National Biodefense Science Board
Dec 20, 2007
|
7.4 KB |
|
| |
New York, New York, December 20, 2007 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced the appointment of the company’s Chief Executive Officer, Dr. Eric Rose, to serve as an ...
|
|
SIGA Completes 21 Day Multi-dose Human Clinical Safety And Dose-ranging Trial Of Its Lead Smallpox Drug ST-246
Dec 6, 2007
|
11.1 KB |
|
| |
New York, New York, December 6, 2007 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its lead drug candidate, ST-246, has successfully completed another human clinical trial.<...
|
|
SIGA Cheif Scientific Officer, Dennis Hruby To Present ST-246 Progress And Human Clinical Safety Study Data To The World Health Organization (WHO)
Nov 26, 2007
|
10.6 KB |
|
| |
New York, New York November 26, 2007 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Scientific Officer, Dr. Dennis Hruby, will be presenting information regard...
|
|
SIGA Technologies to Announce Third Quarter 2007 Results Of Operations
Nov 8, 2007
|
7.9 KB |
|
| |
Company to Host Investor Update Call on November 15, 2007 at 10:00 a.m. EasternNew York, New York November 8, 2007 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that the company’s ...
|
|
ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates
Sep 26, 2007
|
12.4 KB |
|
| |
NEW YORK- (BUSINESS WIRE) - SIGA Technologies, Inc. (NASDAQ: SIGA) today announced that its lead smallpox drug, ST-246, has passed another milestone by demonstrating 100% protection against death in cynomolgus monkeys showing signs of infection with monkeypox virus as part of a primate trial conducted at the U.S. Army Medi...
|
|
SIGA Technologies To Join The Russell Microcap Index
Jun 19, 2007
|
9.1 KB |
|
| |
New York, NY, June 19, 2007 - SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and other antiviral targets, today announced that the company has been selected to join the Russell Microcap™ Index. Russell recently posted a list on ...
|
|
|
= add release to Briefcase
|
